Company research / ZYBT

Zhengye Biotechnology Holding Ltd (ZYBT)

CIK 0001975641 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing

For the year ended 2025-12-31, Zhengye Biotechnology Holding Ltd reported revenue of 116.36M CNY. Revenue fell 37.6% from the prior annual period.

Key ratios (year ended 2025-12-31)

20.5%
Gross margin
-60.6%
Operating margin
-60.0%
Net margin
-22.8%
Return on year-end equity
-37.6%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 6-K (current report) · 2026-08-06

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView